| Status | In progress |
| Decision | Selected |
| Process | HST |
| ID number | 3764 |
Provisional Schedule
| Expected publication | 20 July 2022 |
Project Team
| Project lead | Daniel Davies |
Email enquiries
- If you have any queries please email HST@nice.org.uk
| External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors | Rhythm Pharmaceuticals (setmelanotide) |
| Others | NHS England |
| Department of Health and Social Care | |
| Welsh Government | |
| Patient carer groups | None |
| Professional groups | Royal College of Paediatrics & Child Health |
| Royal College of Physicians | |
| Associated public health groups | None |
| Comparator companies | GlaxoSmithKline Consumer Healthcare (orlistat) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 June 2022 - 17 June 2022 | Final evaluation determination: 3764 |
| 13 April 2022 | Committee meeting: 2 |
| 31 January 2022 - 21 February 2022 | Evaluation consultation |
| 09 December 2021 | Committee meeting: 1 |
| 10 May 2021 | Invitation to participate |
| 07 May 2021 | In progress. In progress |
| 31 July 2020 (14:00) | Scoping workshop (Manchester) |
| 08 June 2020 - 06 July 2020 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual